MedDataX Logo

Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia

NCT ID: NCT01380587

Last Updated: 2013-08-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

25 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-11-30

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine the utility of XCL1 in the prognosis of acute lymphoblastic leukemia.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Each year approximately 256,000 children and adults around the world develop a form of leukemia, and 209,000 died from it. Recently, some studies have evaluated the relationship between the concentration of some cytokines and prognosis of acute lymphoblastic leukemia. XCL1 is a lymphotactin that belongs to a cytokine subfamily called C or γ with only one cysteine in the N-terminal residue. It has been found with significant expression of receptor mRNA XCL1 (XCR1) in T and B lymphocytes and related to hematological neoplasms. For these reasons, XCL1 could be a efficient marker of prognosis in patients with acute lymphoblastic leukemia.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Lymphoblastic Leukemia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

ALL XCL1 Cytokines Prognosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acute Lymphoblastic Leukemia

We will invite patients with newly diagnosed acute lymphoblastic leukemia in the Department of Hematology, who had not received anticancer therapy and regardless the subtype and immunophenotype of the disease.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients with newly diagnosed acute lymphoblastic leukemia .

Exclusion Criteria

* Patients with prior treatment with chemotherapeutic agents.
* Patients treated with immunosuppressants.
* Patients under 12 months old.
* Patients with a diagnosis or history of autoimmune diseases.
* Patients with a diagnosis or history of immunosuppressive diseases.
* Patients who do not agree to sign a Letter of Informed Consent.
Minimum Eligible Age

1 Year

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospital Universitario Dr. Jose E. Gonzalez

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

David Gomez Almaguer

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Cesar H Gutierrez Aguirre, MD

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario Dr. Jose E. Gonzalez UANL

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hospital Universitario Dr. Jose E. Gonzalez UANL

Monterrey, Nuevo León, Mexico

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Mexico

References

Explore related publications, articles, or registry entries linked to this study.

Huang H, Li F, Cairns CM, Gordon JR, Xiang J. Neutrophils and B cells express XCR1 receptor and chemotactically respond to lymphotactin. Biochem Biophys Res Commun. 2001 Feb 23;281(2):378-82. doi: 10.1006/bbrc.2001.4363.

Reference Type BACKGROUND
PMID: 11181058 (View on PubMed)

Taub DD, Oppenheim JJ. Chemokines, inflammation and the immune system. Ther Immunol. 1994 Aug;1(4):229-46.

Reference Type BACKGROUND
PMID: 7584498 (View on PubMed)

Oppenheim JJ, Zachariae CO, Mukaida N, Matsushima K. Properties of the novel proinflammatory supergene "intercrine" cytokine family. Annu Rev Immunol. 1991;9:617-48. doi: 10.1146/annurev.iy.09.040191.003153.

Reference Type BACKGROUND
PMID: 1910690 (View on PubMed)

Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997 Feb 13;385(6617):640-4. doi: 10.1038/385640a0.

Reference Type BACKGROUND
PMID: 9024663 (View on PubMed)

Rollins BJ. Chemokines. Blood. 1997 Aug 1;90(3):909-28. No abstract available.

Reference Type BACKGROUND
PMID: 9242519 (View on PubMed)

Stievano L, Tosello V, Marcato N, Rosato A, Sebelin A, Chieco-Bianchi L, Amadori A. CD8+ alpha beta+ T cells that lack surface CD5 antigen expression are a major lymphotactin (XCL1) source in peripheral blood lymphocytes. J Immunol. 2003 Nov 1;171(9):4528-38. doi: 10.4049/jimmunol.171.9.4528.

Reference Type BACKGROUND
PMID: 14568926 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

XCL1 in ALL

Identifier Type: -

Identifier Source: org_study_id